Drug Management Committee

Drug Management Committee

DMC reports to the HA Directors’ Meeting and is responsible for the overall drug management in HA.  The Committee is supported by various functional committees at both corporate and cluster levels so as to ensure consistency in policy formulation and implementation across HA and clear accountability for drug management at all levels.

Terms of Reference

a)    To recommend drug management policies and formulate relevant guidelines in HA;

b)    To liaise and support implementation of drug policies and guidelines in HA;

c)    To monitor and evaluate impacts of drug policies on judicious use of drugs in HA;

d)    To recommend policies and formulate relevant guidelines for enhancing medication safety in HA;

e)    To conduct Drug Utilisation Review (DUR) in HA for enhancing safe and cost-effective medication therapy management;

f)     To oversee development and management of the Drug Formulary in HA;

g)     To prioritise drug programmes in the annual planning process; and

h)     To endorse the recommendations of new drug listing and prioritisation of drugs for safety net coverage by the Drug Advisory Committee.

Composition

DMC is chaired by the corporate Director overseeing pharmaceutical service management [currently Director (Cluster Services)].  The DMC composition is as follows:

a)     Chairpersons of DAC, DFC, DSC, MSC;

b)     Chairpersons of all Cluster DTCs;

c)     Chief Pharmacist; and

d)     Cluster Clinical Stream Coordinators (Pharmacy) of all clusters.

All DMC members are positional appointments.